Shire, Salix buy way to expansion

Share this article:

Shire expanded its rare-disease portfolio Monday, with the announcement that it has purchased specialty drug company ViroPharma. The $4.2-billion deal moves ViroPharma's Cinryze into Shire's portfolio, along with Plenadren (adrenal insufficiency), Buccolam (seizures), Phase II drug Maribavir (for transplant patients), Phase II compound VP-20621 (for clostridium difficile) and Phase I agent VP-20629 (for Friedreich's Ataxia).

Bloomberg notes that Savvas Neophytou, an analyst at Panmure Gordon & Co., called the deal one “the market had been waiting for.”

The announcement is a bit of a two-step, following last week's news that the company was canning around 180 employees at its Basingstoke, UK, office.

Salix is also expanding. The company announced Friday that it is buying Santarus. The company's excitement about the $2.6-billion deal can be seen on its website, which currently features a pop-up note from CEO Carolyn Logan who calls the deal “transformational for Salix” and one that will allow both companies to expand their reach in ways neither could achieve independently. Both companies offer gastrointestinal therapies.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.